These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37004225)

  • 1. Vonoprazan Therapy is as Effective for Functional Dyspepsia without Heartburn as Acotiamide Therapy.
    Shinozaki S; Osawa H; Hayashi Y; Miura Y; Sakamoto H; Yano T; Lefor AK; Yamamoto H
    J Gastrointestin Liver Dis; 2023 Mar; 32(1):23-29. PubMed ID: 37004225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H
    J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia.
    Porika SK; Veligandla KC; Muni SK; Acharya S; Mehta SC; Sharma AD
    Adv Ther; 2018 Nov; 35(11):1884-1893. PubMed ID: 30350248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
    Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
    Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing and Predictors of Recurrence of Dyspepsia Symptoms after Cessation of Acotiamide Therapy for Functional Dyspepsia: A Long-Term Observational Study.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
    Digestion; 2020; 101(4):382-390. PubMed ID: 31063995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
    Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study.
    Aziz I; Palsson OS; Törnblom H; Sperber AD; Whitehead WE; Simrén M
    Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):252-262. PubMed ID: 29396034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study.
    Funaki Y; Ogasawara N; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Sasaki M; Kasugai K
    Neurogastroenterol Motil; 2020 Feb; 32(2):e13749. PubMed ID: 31612597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Acotiamide Versus Mosapride in Patients With Functional Dyspepsia Associated With Meal-Induced Postprandial Distress Syndrome: A Phase III Randomized Clinical Trial.
    Sinha S; Chary S; Thakur P; Talluri L; Reddy M; K GS; Mohan JM; Jain P; Naik S; C Reddy SV
    Cureus; 2021 Sep; 13(9):e18109. PubMed ID: 34692320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria.
    Tack J; Talley NJ
    Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):134-41. PubMed ID: 23399526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
    Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
    Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Miura Y; Lefor AK; Yamamoto H
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):345-350. PubMed ID: 29253047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Orally Administered Acotiamide Extended-Release Tablets Among Functional Dyspepsia-Postprandial Distress Syndrome Patients: A Randomized, Double-Blind, Multicenter Study.
    Sinha SD; Sinha SK; Talluri L; Bhashyakarla RK; Malladi U; Dosi RV; Jain MK; Chary S; Reddy M; Thakur P
    Cureus; 2021 Apr; 13(4):e14361. PubMed ID: 33968542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heartburn and dyspepsia symptom severity improves after treatment and correlates with histology in adults with eosinophilic esophagitis.
    Eluri S; Perjar I; Betancourt R; Randall C; Raja S; Woosley JT; Shaheen NJ; Dellon ES
    Dis Esophagus; 2019 Nov; 32(9):. PubMed ID: 31329864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
    Xiao G; Xie X; Fan J; Deng J; Tan S; Zhu Y; Guo Q; Wan C
    ScientificWorldJournal; 2014; 2014():541950. PubMed ID: 25197703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
    Roorda AK; Marcus SN; Triadafilopoulos G
    Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
    Jones R; Crouch SL
    Aliment Pharmacol Ther; 1999 Mar; 13(3):413-9. PubMed ID: 10102976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
    Matsushita M; Masaoka T; Suzuki H
    Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
    Altan E; Masaoka T; Farré R; Tack J
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.